Non-coding ribonucleic acid-mediated CAMSAP1 upregulation leads to poor prognosis with suppressed immune infiltration in liver hepatocellular carcinoma

Wenwen Wang, Jingjing Zhang, Yuqing Wang, Yasi Xu and Shirong Zhang*

Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China

Liver hepatocellular carcinoma (LIHC) is well-known for its unfavorable prognosis due to the lack of reliable diagnostic and prognostic biomarkers. Calmodulin-regulated spectrin-associated protein 1 (CAMSAP1) is a non-centrosomal microtubule minus-end binding protein that regulates microtubule dynamics. This study aims to investigate the specific role and mechanisms of CAMSAP1 in LIHC. We performed systematical analyses of CAMSAP1 and demonstrated that differential expression of CAMSAP1 is associated with genetic alteration and DNA methylation, and serves as a potential diagnostic and prognostic biomarker in some cancers, especially LIHC. Further evidence suggested that CAMSAP1 overexpression leads to adverse clinical outcomes in advanced LIHC. Moreover, the AC145207.5/LINC01748-miR-101-3p axis is specifically responsible for CAMSAP1 overexpression in LIHC. In addition to the previously reported functions in the cell cycle and regulation of actin cytoskeleton, CAMSAP1-related genes are enriched in cancer- and immune-associated pathways. As expected, CAMSAP1-associated LIHC is infiltrated in the suppressed immune microenvironment. Specifically, except for immune cell infiltration, it is significantly positively correlated with immune checkpoint genes, especially CD274 (PD-L1), and cancer-associated fibroblasts. Prediction of immune checkpoint blockade therapy suggests that these patients may benefit from therapy. Our study is the first to demonstrate that besides genetic alteration and DNA methylation, AC145207.5/LINC01748-miR-101-3p-mediated CAMSAP1 upregulation in advanced LIHC leads to poor prognosis with suppressed immune infiltration, representing a potential diagnostic and prognostic biomarker as well as a promising immunotherapy target for LIHC.

KEYWORDS
CAMSAP1, immune infiltration, hepatocellular carcinoma, non-coding RNA, prognosis
Introduction

Liver hepatocellular carcinoma (LIHC) is the sixth most commonly diagnosed cancer and the third major cause of cancer-related death worldwide, according to the Global Cancer Statistics report 2020 (Sung et al., 2021). Over 910,000 patients develop LIHC every year, and approximately 830,000 patients die from it. The common risk factors for LIHC include chronic viral infection (Pawlotsky, 2004; Trepo et al., 2014), non-alcoholic fatty liver disease (Hindson, 2021), excessive alcohol consumption (Gao and Bataller, 2011), obesity (Lee et al., 2021), aflatoxin exposure (Kimanya et al., 2021), hemochromatosis (Olynyk and Ramm, 2021), primary cholangitis (Lundberg Bave et al., 2021), and immune system diseases (Marcucci and Rumio, 2021). Despite the availability of multiple diagnostic biomarkers for LIHC, their reliability remains questionable, thereby contributing to poor prognosis (Ahn et al., 2021). Therefore, there is an urgent need to identify new biomarkers associated with tumor stage and prognosis to assist the early diagnosis, treatment, and patient management in LIHC.

The microtubule (MT) skeleton is a critical molecular target for tumor therapy (Jordan and Wilson, 2004; Jackson et al., 2007), and MT-associated proteins play essential roles in cell proliferation, polarization, and migration by regulating MT assembly and dynamics (Goodson and Jonasson, 2018). In recent years, as non-centrosomal MT minus binding proteins, members of the Calmodulin-regulated spectrin-associated protein (CAMSAP) family, including CAMSAP1, CAMSAP2, and CAMSAP3, have attracted increasing attention for their role in cancers. CAMSAP1 mutation is a potential prognostic biomarker for small cell lung cancer, indicating platinum sensitivity in lung cancer patients (Yi et al., 2021). Loss of CAMSAP3 induces senescence in lung cancer cells by regulating the activity of extracellular signal-regulated kinase (Wattanathamsan et al., 2021). CAMSAP2 expression is upregulated in LIHC and leads to tumor metastasis and poor prognosis (Li D. et al., 2020). Interestingly, different from the entire MT minus binding of CAMSAP2 and CAMSAP3, CAMSAP1 specifically binds to the minus ends of the free or growing MT, protects the minus ends from depolymerization but does not affect the growth rate of the minus, thus accurately regulating MT minus-end protection and resulting in asymmetric distribution of MTs (Liu et al., 2020). Moreover, CAMSAP1 is downregulated by miR-126 upregulation in primary human osteoblasts co-cultured with human umbilical vein endothelial cells, thus promoting the differentiation of 2 cell types (Strasburg et al., 2017); Meanwhile, in laryngeal squamous cell carcinoma, CAMSAP1 and protein expression are also negatively regulated by miR-126, and loss of miR-126 induces MT formation and aggregation, thus promoting tumor metastasis (Sun et al., 2014). However, the expression, diagnosis, survival, and correlation analyses of CAMSAP1 with tumor immune infiltration in LIHC have not been comprehensively evaluated.

In this study, we conducted comprehensive pan-cancer analyses of CAMSAP1 and demonstrated that CAMSAP1 expression is associated with genetic alteration and DNA methylation. Additionally, AC145207.5/LINC01748-miR-101–3p constitutes an upstream non-coding RNA (ncRNA) axis that regulates CAMSAP1 expression in LIHC. Overexpressed CAMSAP1 leads to poor prognosis in advanced LIHC. Finally, the relationship between CAMSAP1 expression and immune infiltration was investigated. Collectively, we suggest that the ncRNA-mediated CAMSAP1 overexpression is associated with unfavorable LIHC prognosis with suppressed immune infiltration and immune checkpoint blockade (ICB) treatment may be effective for these patients.

Materials and methods

Data acquisition and processing

Transcriptome data including mRNA, microRNA (miRNA), long non-coding RNA (lncRNA), and clinical information were downloaded from The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/repository) and UCSC Xena (https://xenabrowser.net) databases (Liu et al., 2018). Among them, TCGA database contains mRNA and lncRNA sequencing data in level 3 HTSeq-FPKM format, and miRNA sequencing data in level 3 BCGSC format, all of them need to be converted into TPM and RPM format, respectively. UCSC Xena database contains both TCGA and Genotype-Tissue Expression (GTEx) data, which is processed by the Toil process into TPM format (Vivian et al., 2017). GSE45267 dataset comprising 39 normal and 48 LIHC samples were downloaded from the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) database, and converted into TPM format (Wang et al., 2013). All the TPM, RPM, and clinical data were used for the following analyses, including expression, correlation, diagnoses, and survival analyses. R software (Version 3.6.3) and ggplot2 package (Version 3.3.3) were used for statistical analyses and visualization, respectively.
Differential expression analysis

Differential expression analysis of CAMSAP1 was performed using TCGA and/or GTEx databases (Frost et al., 2020; Iuzzi et al., 2020), and Oncomine data containing 424 sets of analyses were used for further verification (threshold: \( p < 0.0001 \); fold change \( >1.5 \); gene rank: top 10\%). For CAMSAP1 expression in LIHC, GSE45267 dataset was also used. For CAMSAP1 protein expression in LIHC, immunohistochemical (IHC) images from the Human Protein Atlas portal (HPA, https://www.proteinatlas.org/) were used and the average optical density (AOD) of CAMSAP1 staining was measured by ImageJ software (NIH). For miRNA and lncRNA expression analyses, datasets from TCGA and/or GTEx were used. All these analyses were conducted with unpaired Wilcoxon rank-sum test and represented as histograms or violin plots.

Genetic alteration and methylation level analysis

The cBioPortal (http://www.cbioportal.org/) was used to analyze genetic alteration (TCGA, Pan-Cancer Atlas) and DNA methylation (TCGA, Firehose) of CAMSAP1. Correlation plots of CAMSAP1 expression with copy-number alterations (CNAs) and DNA methylation were downloaded directly from cBioPortal and displayed as heatmaps. Histograms representing CAMSAP1 promoter methylation levels in normal tissue and primary tumor were downloaded from the UALCAN portal (http://ualcan.path.uab.edu/index.html). The beta value 0.5–0.7 was considered hypermethylation, and 0.25–0.3 was hypomethylation.

Prediction of CAMSAP1-associated miRNAs and long non-coding ribonucleic acids

The Encyclopedia of RNA Interactomes portal (ENCORI, https://rna.sysu.edu.cn/encori/index.php) was used to analyze CAMSAP1-miRNA, lncRNA-miRNA, and lncRNA-CAMSAP1 relationships in several cancers (Li et al., 2014). Firstly, seven target-predicting programs were used to predict the correlation between CAMSAP1 and miRNA (parameter setting: assembly, hg38; CLIP-Data \( \geq 5 \); pan-Cancer \( \geq 1 \); programNum \( \geq 2 \); target, CAMSAP1). Then, miRanda was used to predict the correlation between miRNA and lncRNA (parameter setting: assembly, hg38; miRNA: hsa-miR-101–3p, CLIP-Data \( \geq 5 \); pan-Cancer \( \geq 1 \)) (Hoadley et al., 2014). All these correlation analyses were conducted online, and the resulting correlation plots were downloaded and displayed as lollipops.

Differential expression analysis of CAMSAP1, miRNA, and lncRNA

The diagnostic values of CAMSAP1, miRNA and lncRNA were estimated by the receiver operating characteristic (ROC) curve using the pROC R package (Version 1.17.0.1, https://cran.r-project.org/web/packages/pROC/index.html). The area under the curve (AUC) > 0.9 was considered to represent high diagnostic value, whereas 0.7–0.9 was median, and 0.5–0.7 was low.

Survival analyses of CAMSAP1-upregulated and -downregulated cancers, including overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI), were conducted by Kaplan–Meier (KM) analyses and represented by a forest plot. For LIHC, patients were divided according to the expression of CAMSAP1, miRNAs, and lncRNAs, and KM analyses were used to evaluate the prognostic value. Survivin R (Version 3.2–10, https://cran.r-project.org/web/packages/survivalAnalysis/index.html) and survminer R package (Version 0.4.9, https://cran.r-project.org/web/packages/survminer/index.html) were used for statistical analyses and visualization.

Correlation analyses between CAMSAP1 expression and clinical features

The correlation between CAMSAP1 expression and clinical features in LIHC from TCGA database was analyzed as a baseline datasheet using the Chi-square test or Fisher’s exact test. In addition, an unpaired Wilcoxon rank-sum test and logistic regression analysis were performed to product violin plots and forest plots, respectively.

Clinical statistical analysis on prognosis, model construction, and evaluation

Univariate and multivariate Cox regression analyses were used to compare the effects of CAMSAP1 expression and other clinical characteristics on survival rate. Bars represent 95% confidence intervals (CI) of hazard ratio (HR). Survivin R package was used for survival data statistics and represented by forest plots.

Based on multivariate Cox regression, nomogram was designed using the rms R package (Version 6.2–0, https://cran.r-project.org/web/packages/rms/index.html) and survival R package. Calibration curves and concordance index (C-index) were used to compare the accuracy of the nomogram model. The C-index > 0.9 indicated high accuracy, 0.7–0.9 indicated median, and 0.5–0.7 indicated low (Liu et al., 2018).
Functional enrichment analysis of CAMSAP1-related differentially expressed genes

CAMSAP1-associated DEGs in LIHC were identified using the limma R package (Version 3.40.2, http://bioconductor.org/packages/3.9/bioc/src/contrib/Archive/limma/), and presented by a volcano plot (Love et al., 2014). The correlation between CAMSAP1 and the top 20 DEGs was assessed through a heatmap. Functional enrichment analysis of these DEGs was conducted by Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA). GO analysis is a common method for annotating functional genes, especially cellular component (CC), molecular function (MF), and biological pathway (BP), and represented by bubble plots. GSEA was conducted to detect phenotypes and signaling pathways. Statistical analysis and graphical charting of GO and GSEA data were performed using the clusterProfiler R package (Version 3.14.3, http://bioconductor.riken.jp/packages/3.10/bioc/html/clusterProfiler.html) (Yu et al., 2012; Love et al., 2014).

Immune infiltration analysis

Tumor Immune Estimation Resource 2 (TIMER2, http://timer.cistrome.org) is a comprehensive resource for systematic analysis of immune infiltrates across diverse cancer types. It was used to analyze the correlation between CAMSAP1 expression and immune cells, immune cell markers, immune checkpoints, and cancer-associated fibroblasts (CAFs) in LIHC (Li T. et al., 2020; Wu et al., 2020; Yi et al., 2020). TCGA datasets were also used to evaluate the spearman correlation between CAMSAP1 expression and immune cell markers, immune checkpoints, tumor mutation burden (TMB), and microsatellite instability (MSI) in LIHC, and represented by scatter plots or heatmaps (Bonneville et al., 2017; Thorsson et al., 2018).

Tumor Immune Dysfunction and Exclusion (TIDE, http://tide.dfci.harvard.edu/) module uses a set of markers to evaluate two different tumor immune escape mechanisms, including tumor-infiltrating cytotoxic T lymphocyte (CTL) dysfunction and rejection by immunosuppressive factors including immune checkpoint genes. High TIDE score indicated poor efficacy and short survival after ICB treatment.

Results

Pan-cancer expression of CAMSAP1 is associated with genetic alteration and deoxyribonucleic acid methylation

To explore the possible mechanism of CAMSAP1 in tumorigenesis, we conducted a series of data collection and analyses (Figure 1). First, we compared its expression in 33 types of human cancer and normal samples using datasets from the UCSC Xena database. CAMSAP1 expression was found to be upregulated in breast infiltrating carcinoma (BRCA), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), diffuse large B cell lymphoma (DLBC), esophageal carcinoma (ESCA), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), low-grade glioma (LGG), LIHC, lung squamous cell carcinoma (LUSC), pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD), and thymoma (THYM). In contrast, its expression was significantly downregulated in adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), kidney chromophobe (KICH), bladder urothelial carcinoma (LAML), lung adenocarcinoma (LUAD), ovarian serous cystadenocarcinoma (OV), skin melanoma (SKCM), testicular germ cell tumors (TGCT), uterine corpus endometrial carcinoma (UCEC), and uterus carcinosarcoma (UCS) (p < 0.05). However, there was no significant difference in CAMSAP1 expression in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), pheochromocytoma and paraganglioma (PCPG), prostate cancer (PRAD), rectum adenocarcinoma (READ), and thyroid cancer (THCA) (Figure 2A).

Next, we used the Oncomine database to verify CAMSAP1 expression and found that the expression was significantly increased in colorectal, gastric, kidney, liver, and pancreatic cancers. In contrast, its expression was decreased in brain and central nervous system, cervical, esophageal, head and neck, lung, ovarian, and prostate cancers, as well as in melanoma and sarcoma (Figure 2B).

The susceptibility of genetic variation to cancer is well known. Therefore, we first used cBioPortal (TCGA, Pan-Cancer Atlas) to study the relationship between CAMSAP1 expression and genetic variation. CAMSAP1 genetic variation included amino acid mutation and CNAs, among these 32 cancer types (COAD and READ are merged into COADREAD), 25 of them contained CAMSAP1 mutation, and 22 had CNAs (Figure 2C). UCEC and STAD had the highest alteration frequency (>5%), while DLBC, mesothelioma (MESO), PCPG, and THYM had no alteration. CNAs are the genetic variation most associated with CAMSAP1 expression (Lee et al., 2008), and most of the 22 cancers showed positive correlation with its expression, especially ACC (r = 0.64, p = 4.03e-10), OV (r = 0.61, p = 9.43e-32), and BLCA (r = 0.53, p = 6.56e-31) (Figure 2D; Supplementary Table S1). DNA methylation directly affects mRNA expression (Men et al., 2017; Skvortsova et al., 2019). As one of the regulation mechanisms, CAMSAP1 expression and promoter methylation level were not completely uniform. The methylation level was decreased in BLCA, CESC, ESCA, HNSC, LIHC, LUAD, LUSC, THCA, and UCEC tissues compared to normal tissues according to the UALCAN portal; meanwhile, it was greatly increased in BRCA, KIRC, PRAD, and SARC.
However, no significant difference was observed in other cancers (Supplementary Figure S1). Next, we investigated the correlation between CAMSAP1 expression and DNA methylation from cBioPortal (TCGA, firehose). DNA methylation was negatively correlated with CAMSAP1 expression, especially for THYM (r = −0.58, p = 4.94e-12), DLBC (r = −0.57, p = 2.628e-5), and THCA (r = −0.48, p = 4.19e-31) (Figure 2F; Supplementary Table S2).

Combined with UCSC Xena and Oncomine databases, CHOL, COAD, KIRC, KIRP, LIHC, PAAD, and STAD were chosen for CAMSAP1 upregulation studies, whereas LUAD, OV, and SKCM were selected for downregulation research. Taken together, these results suggest that CAMSAP1 expression may play an important regulatory role in the carcinogenesis of at least 10 cancer types.

Differentially expressed CAMSAP1 serves as a potential diagnostic and prognostic biomarker in some cancers

To confirm the suggestion, we evaluated the diagnostic value and survival effect of CAMSAP1 in cancers. ROC analyses indicated that CAMSAP1 was a diagnostic molecule with significantly high or median values in CHOL (AUC = 0.981), COAD (0.895), KIRP (0.726), LIHC (0.805), PAAD (0.930), and OV (0.720), whereas low values in KIRC (0.677), STAD (0.688), LUAD (0.555), and SKCM (0.555) (Figures 3A,B).

Prognostic analyses were then performed (Figure 3C; Supplementary Figure S2). In the CAMSAP1-upregulated groups, LIHC patients had poor prognosis, including OS (HR = 1.83, 95% CI = 1.24–2.71, p = 0.002), DSS (HR = 2.30, 95% CI = 1.36–3.91, p = 0.002), and PFI (HR = 1.75, 95% CI = 1.30–2.35, p < 0.001); meanwhile, COAD (HR = 1.68, 95% CI = 1.08–2.61, p = 0.021) and PAAD (HR = 1.49, 95% CI = 1.01–2.20, p = 0.044) patients only had poor PFI. However, KIRC patients exhibited favorable prognosis for OS (HR = 0.37, 95% CI = 0.25–0.56, p < 0.001), DSS (HR = 0.41, 95% CI = 0.28–0.59, p < 0.001), and PFI (HR = 0.43, 95% CI = 0.31–0.59, p < 0.001).

Surprisingly, in the CAMSAP1-downregulated groups, OS (HR = 1.36, 95% CI = 1.02–1.81, p = 0.033) for OV patients, and OS (HR = 1.60, 95% CI = 1.22–2.11, p = 0.001), DSS (HR = 1.62, 95% CI = 1.20–2.19, p = 0.002), and PFI (HR = 1.30, 95% CI = 1.03–1.64, p = 0.026) for SKAM patients were increased significantly. Due to the low diagnostic value in KIRC and SKCM, CAMSAP1 serves as a novel diagnostic and prognostic biomarker in LIHC.

Overexpressed CAMSAP1 leads to adverse clinical outcomes in advanced liver hepatocellular carcinoma

Dataset from GEO further confirmed the high expression of CAMSAP1 in LIHC (GSE45267, p = 0.02) (Figure 4A). IHC staining from the HPA portal also showed prominent CAMSAP1 antibody staining in LIHC tissue (p = 2.9e-03) (Figures 4B,C; Supplementary Figure S3). Based on these findings, we confirmed that CAMSAP1 mRNA and protein are significantly upregulated in LIHC.

Subsequently, clinical data from 371 LIHC patients were obtained from TCGA database to evaluate the relationship between CAMSAP1 expression and clinical features (Table 1). The cohort comprised 121 females (32.6%) and 250 males (67.4%) with an average age and weight of 60 years and 70 kg, respectively. Results showed that CAMSAP1 expression was significantly correlated with the weight (p = 0.04), T stage (2.8e-04), pathologic stage (3.4e-04), histologic grade (8e-03), tumor status (6e-03), and residual tumor (0.01) (Figure 4D). Univariate logistic regression analysis further demonstrated that CAMSAP1 expression was a categorical dependent variable associated with clinical features of adverse prognosis. CAMSAP1 expression was positively correlated with weight (odds ratio (OR) = 0.713, 95% CI = 0.512–0.985, p = 0.042),
Pan-cancer expression of CAMSAP1 is associated with genetic alteration and DNA methylation. (A) The expression of CAMSAP1 in normal versus 33 types of tumor tissues from UCSC Xena database. ns: $p \geq 0.05$, *: $p < 0.05$, **: $p < 0.01$, ***: $p < 0.001$. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast infiltrating carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, diffuse large B cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma, KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain low-grade glioma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MEES, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SRCC, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma. (B) The expression of CAMSAP1 from the Oncomine portal. Red represented high expression in cancer, blue represented low expression in cancer, and the number in the table represented datasets that meet the threshold. The threshold was $p < 0.0001$, fold change $>1.5$ and gene rank $= 10\%$. (C,D) CAMSAP1 genetic variation (C) and its correlation with CNAs (D) in pan-cancer from cBioPortal. (E) CAMSAP1 promoter methylation in normal and primary tumor from UALCAN portal. (F) Correlation between CAMSAP1 and DNA methylation from cBioPortal. *: $p < 0.05$, **: $p < 0.01$. 
T stage (OR = 1.902, 95% CI = 1.338–2.736, \( p < 0.001 \)), pathologic stage (OR = 1.927, 95% CI = 1.340–2.809, \( p < 0.001 \)), histologic grade (OR = 1.401, 95% CI = 1.021–1.935, \( p = 0.038 \)), tumor status (OR = 1.510, 95% CI = 1.099–2.093, \( p = 0.012 \)), and residual tumor (OR = 2.529, 95% CI = 1.222–5.342, \( p = 0.013 \)) (Figure 4E). These results suggest that high CAMSAP1 expression is more likely to be observed in LIHC patients with more advanced stage and grade.

To further confirm the relationship between CAMSAP1 expression and poor prognostic outcome in LIHC, we performed additional univariate Cox regression analyses. Overall, high CAMSAP1 expression was significantly correlated with poor OS (HR = 1.577, 95% CI = 1.206–2.061, \( p < 0.001 \)) (Figure 4F, left) and DSS (HR = 1.495, 95% CI = 1.051–1.216, \( p = 0.025 \)) (Supplementary Figure S4A, left) as well as poor PFI (HR = 1.554, 95% CI = 1.234–1.957, \( p < 0.001 \)) (Supplementary Figure S5A, left). To identify factors related to survival, multivariate Cox regression analysis was performed. CAMSAP1 expression remained an independent factor associated with OS (HR = 1.577, 95% CI = 1.206–2.061, \( p < 0.001 \)) (Figure 4F, left) and PFI (HR = 1.495, 95% CI = 1.051–1.216, \( p = 0.025 \)) (Supplementary Figure S4A, left). In addition to genetic alteration and DNA methylation regulation in pan-cancer, we introduced ncRNAs well-known for their role in regulating gene expression to further explore the regulatory mechanism of CAMSAP1 overexpression in LIHC (Anastasiadou et al., 2018). Firstly, the ENCORI portal predicted the AC145207.5/LINC01748-miR-101–3p axis is specifically responsible for CAMSAP1 overexpression in liver hepatocellular carcinoma.
Overexpressed CAMSAP1 leads to adverse clinical outcomes in advanced LIHC. (A) The expression of CAMSAP1 in LIHC from the GEO database. (B) IHC images of CAMSAP1 proteins with antibody HPA024161 in normal and LIHC tissues from the HPA database. Scale bar, 200 μm. (C) Statistical analysis of CAMSAP1 IHC intensity. (D) Violin plots of correlation between CAMSAP1 expression and clinical features. (E) A forest plot of univariate Logistic regression analysis of the correlation between CAMSAP1 expression and clinical features. (F) A forest plot of univariate and multivariate Cox regression analyses with OS. *p < 0.05, **p < 0.01, ***p < 0.001. (G) A nomogram prediction model with 1-, 3-, and 5-years OS. (H) Nomogram calibration analysis with OS.
Table 1: Correlation between CAMSAP1 expression and clinical variables in LIHC based on TCGA database.

| Characteristic              | Low expression | High expression | p   |
|----------------------------|----------------|-----------------|-----|
| n                          | 185            | 186             | 0.130 |
| Gender, n (%)              |                |                 |     |
| Female                     | 53 (14.3%)     | 68 (18.3%)      |     |
| Male                       | 132 (35.6%)    | 118 (31.8%)     |     |
| Race, n (%)                |                |                 | 0.498 |
| Asian                      | 80 (22.3%)     | 78 (21.7%)      |     |
| Black or African American  | 10 (2.8%)      | 7 (1.9%)        |     |
| White                      | 85 (23.7)      | 99 (27.6%)      |     |
| Age, n (%)                 |                |                 | 0.096 |
| ≤60                        | 80 (21.6%)     | 97 (26.2%)      |     |
| >60                        | 105 (28.4%)    | 88 (23.8%)      |     |
| Weight, n (%)              |                |                 | 0.100 |
| ≤70                        | 85 (24.7%)     | 97 (28.2%)      |     |
| >70                        | 91 (26.5%)     | 71 (20.6%)      |     |
| T stage, n (%)             |                |                 | 0.046* |
| T1                         | 102 (27.7%)    | 79 (21.5%)      |     |
| T2                         | 44 (12.1%)     | 50 (13.6%)      |     |
| T3                         | 31 (8.4%)      | 49 (13.3%)      |     |
| T4                         | 5 (1.4%)       | 8 (2.2%)        |     |
| N stage, n (%)             |                |                 | 1.000 |
| N0                         | 117 (45.7%)    | 135 (52.7%)     |     |
| N1                         | 2 (0.8%)       | 2 (0.8%)        |     |
| Pathologic stage, n (%)    |                |                 | 0.361 |
| Stage I                    | 95 (27.4%)     | 76 (21.9%)      |     |
| Stage II                   | 41 (11.8%)     | 45 (13.3%)      |     |
| Stage III                  | 30 (8.6%)      | 55 (15.9%)      |     |
| Stage IV                   | 4 (1.2%)       | 1 (0.3%)        |     |
| Histologic grade, n (%)    |                |                 | 0.003** |
| G1                         | 36 (9.8%)      | 19 (5.2%)       |     |
| G2                         | 95 (26%)       | 82 (22.4%)      |     |
| G3                         | 46 (12.6%)     | 76 (20.8%)      |     |
| G4                         | 5 (1.4%)       | 7 (1.9%)        |     |
| Tumor status, n (%)        |                |                 | 0.018* |
| Tumor free                 | 112 (31.8%)    | 89 (25.3%)      |     |
| With tumor                 | 64 (18.2%)     | 87 (24.7%)      |     |
| Residual tumor, n (%)      |                |                 | 0.025* |
| R0                         | 168 (49.1%)    | 156 (45.6%)     |     |
| R1                         | 4 (1.2%)       | 13 (3.8%)       |     |
| R2                         | 1 (0.3%)       | 0 (0%)          |     |
| Adjacent hepatic tissue inflammation, n (%) |                |                 | 0.17 |
| None                       | 67 (28.6%)     | 50 (21.4%)      |     |
| Mild                       | 44 (18.8%)     | 55 (23.5%)      |     |
| Severe                     | 9 (3.8%)       | 9 (3.8%)        |     |
| Vascular invasion, n (%)   |                |                 | 0.024* |
| No                         | 114 (36.2%)    | 92 (29.2%)      |     |
| Yes                        | 45 (14.3%)     | 64 (20.3%)      |     |

*p < 0.05, **p < 0.01.
we confirmed that the AC145207.5/LINC01748-miR-101-3p constitutes an upstream ncRNA axis that regulates CAMSAP1 expression in LIHC.

**CAMSAP1-related differentially expressed genes are enriched in immune-associated pathways**

Based on the different expression of CAMSAP1 between normal and LIHC tissues, LIHC patients were divided into high- and low-CAMSAP1 expression groups, and the mRNA profile of the two groups was compared. A total of 338 DEGs were found to be statistically significant between the two groups, including 279 upregulated and 59 downregulated genes (adjusted \( p < 0.05 \) and \( \log_{2}FC > 1 \) (Figure 6A). The correlation between CAMSAP1 and the top 20 DEGs are illustrated in a heatmap (Figure 6B; Supplementary Table S5).

To further predict the functional enrichment of CAMSAP1 interactive genes in LIHC, GO and GSEA enrichment analyses were performed. Overall, CAMSAP1-related DEGs were enriched in 1) CCs: the collagen-containing extracellular matrix, spindle, and microtubule; 2) MFs: cell adhesion molecule binding, extracellular matrix structural constituent, and integrin binding; and 3) BPs: extracellular structure organization, cell-substrate adhesion, and nuclear division (Figure 6C; Supplementary Table S6). GSEA enrichment was performed to identify CAMSAP1 expression-related signaling pathways. Results suggested that genes were significantly enriched in the cell cycle (Figure 6D), regulation of actin cytoskeleton (Figure 6E), cancer-related pathways (Pathways in cancer, TGF-beta signaling pathway, Notch signaling pathway, Wnt signaling pathway, Erbb signaling pathway) (Figure 6F), and immune system (T cell receptor signaling pathway) (Figure 6G), implying that CAMSAP1-related genes may also be involved in immune regulation (Supplementary Table S7).

**CAMSAP1-associated liver hepatocellular carcinoma is infiltrated in the suppressed immune microenvironment**

The tumor immune microenvironment is complex, generally being positively regulated by immune cell infiltration and negatively regulated by immune checkpoints, CAFs, and other factors, thus determining the tumor prognosis. The GSEA enrichment of CAMSAP1-associated genes implied that they could function in immune regulation. Therefore, we investigated whether CAMSAP1 expression in LIHC was associated with immune infiltration using the TIMER2 portal. From CAMSAP1 arm-level deletion to high amplification, B cell (\( p = 0.0015 \)), CD4+ T cell (0.0051), and myeloid dendritic cell (0.0051) infiltration levels were increased (Figure 7A). CAMSAP1 expression was positively correlated with all the immune cells analyzed, including B cells (\( Rho = 0.242, p = 5.27e-06 \)), CD4+ T cells (\( Rho = 0.224, p = 2.59e-05 \)), CD8+ T cells (\( Rho = 0.174, p = 1.14e-03 \)), macrophages (\( Rho = 0.378, p = 3.67e-13 \)), myeloid dendritic cells (\( Rho = 0.429, p = 6.91e-17 \)), and neutrophils (\( Rho = 0.375, p = 5.57e-13 \)) in LIHC using the TIMER2 portal, especially for those of macrophages, myeloid dendritic cell, and neutrophil (\( Rho > 0.3, p < 0.001 \)) (Figure 7B). Next, we evaluated the relationship between CAMSAP1 and various immune cell markers in LIHC using the TIMER2 and TCGA databases to further explore the role of CAMSAP1 in immune infiltration. The expression of CAMSAP1 was positively correlated with most of these genes, especially IRF5 and PTGS2 of M1 macrophages, NRPI and ITGAX of myeloid dendritic cells, and ITGAM of neutrophils (\( Rho > 0.3, p < 0.001 \)) (Figure 7C; Supplementary Figure S6A; Supplementary Table S8). These findings support that CAMSAP1 is positively correlated to immune cell infiltration, especially innate immune cells.

Based on the previous results, we also conducted a comprehensive study from immune suppression and promotion to further explore the regulation mechanism of CAMSAP1-related LIHC immune infiltration. Important immune checkpoint genes responsible for tumor immune escape include CD274, CTLA4, HAVCR2, LAG3, PD1D1, PDCD1LG2, SIGLEC15, and TIGIT. Considering the possible tumorigenic role of CAMSAP1 in LIHC, we evaluated the correlation between CAMSAP1 expression and these genes. CAMSAP1 expression had no correlation with LIHC purity, LAG3, and SIGLEC15, whereas it was positively correlated with CD274 (\( Rho = 0.486, p = 7.06e-22 \)), CTLA4 (\( Rho = 0.169, p = 1.58e-03 \)), HAVCR2 (\( Rho = 0.377, p = 4.49e-13 \)), PDCD1 (\( Rho = 0.186, p = 5.15e-4 \)), PDCD1LG2 (\( Rho = 0.221, p = 3.57e-05 \)), and TIGIT (\( Rho = 0.265, p = 6.15e-07 \)) in LIHC using the TIMER2, especially for HAVCR2, and CD274 (\( Rho > 0.3, p < 0.001 \)). Correlation analysis using TCGA dataset also confirmed that CAMSAP1 was positively correlated with CD274 (\( r = 0.341, p < 0.001 \)), CTLA4 (\( r = 0.15, p = 0.004 \)), HAVCR2 (\( r = 0.27, p < 0.001 \)), PDCD1 (\( r = 0.177, p = 0.001 \)), PDCD1LG2 (\( r = 0.158, p = 0.002 \)), SIGLEC15 (\( r = 0.117, p = 0.024 \)), TIGIT (\( r = 0.165, p = 0.001 \)), especially CD274 (\( r > 0.3, p < 0.001 \)), whereas LAG3 was not correlated with CAMSAP1. Previous studies have indicated that CAFs in the stroma regulate different tumor infiltrating immune cells and participate in immunosuppression. Therefore, we employed the EPIC, MCPCOUNTE, and TIDE algorithms using TIMER2 to investigate the correlation between CAFs and CAMSAP1 expression. Results showed that CAMSAP1 expression was positively correlated with CAFs infiltration in LIHC (\( Rho = 0.442, p = 5.86e-18 \)), Rho = 0.346, \( p = 3.89e-11 \); Rho = 0.393, \( p = 3.72e-14 \) (Figure 7D; Supplementary Figure S6B; Supplementary Table S9).

TMB and MSI are two emerging biomarkers that promote immune cell infiltration and reflect patient response to...
FIGURE 5
The AC145207.5/LINC01748-miR-101–3p axis is specifically responsible for CAMSAP1 overexpression in LIHC. (A,G) Lollipop plots of spearman correlation between CAMSAP1 and predicted miRNAs (A), miR-101–3p, and predicted lncRNAs (G) from ENCORI portal. *p < 0.05, **p < 0.01. (B,H) The expression of negatively correlated miRNAs of CAMSAP1 (B) and negatively correlated lncRNAs of miR-101–3p (H) in normal and LIHC tissues from TCGA and TCGA plus GTEx database. *p < 0.05, **p < 0.01, ***p < 0.001. (C,I) ROC analyses of negatively correlated miRNAs (C) and lncRNAs (I). (D,E,J,K) KM analyses for OS and DSS of negatively correlated miRNAs (D,E) and lncRNAs (J,K). (F,L) The pairing sequence of CAMSAP1-miR-101–3p (F), miR-101–3p-AC145207.5 and miR-101–3p-LINC01748 (L). (M) Scatter plots of correlation between CAMSAP1 and AC145207.5 and LINC01748. p < 0.05 indicated a significant difference.
immunotherapy. For tumor cells with a higher TMB score, the stronger antigenicity it has, the more tumor cells can be recognized by immune cells, thus promoting immune infiltration. Tumor cells with higher MSI scores indicate that somatic cells are over-mutated and the tumor expresses more neoantigens, thus promoting immune cell infiltration. Unfortunately, CAMSAP1 expression was not correlated with TMB ($r = -0.035$, $p = 0.541$) or MSI ($r = 0.056$, $p = 0.287$) (Figure 7D; Supplementary Figures S6C,D; Supplementary Table S9).

Next, we used the TIDE algorithm to predict the ICB treatment effect. Results showed that compared with the high CAMSAP1 expression group, the low group exhibited a lower TIDE score, indicating a better therapeutic outcome (Figure 7E; Supplementary Table S10). Collectively, these results demonstrated that in addition to immune cell infiltration, tumor immune escape mediated by immune checkpoints and CAFs is also involved in CAMSAP1-mediated LIHC progression and ICB treatment is effective in these patients.

Discussion

The early stages of LIHC are typically asymptomatic or atypical; thus, elucidating the underlying molecular mechanisms of LIHC may contribute to the identification of interesting diagnostic and prognostic biomarkers or the development of viable therapeutic targets. This study conducted pan-cancer analyses of CAMSAP1 expression, and demonstrated that CAMSAP1 upregulation was associated with advanced tumor and unfavorable prognosis in LIHC.

It is well known that ncRNAs, comprising miRNAs, lncRNAs, and circular RNAs, communicate with each other and play a role in regulating gene expression (Anastasiadou et al., 2018). Therefore, ENCORI were used to investigate the upstream regulated miRNAs of CAMSAP1. Five miRNAs were found to be negatively correlated with CAMSAP1, and three of them were downregulated in LIHC. Previous studies have demonstrated that most miRNAs serve as tumor-suppressors in LIHC. For example, miR-885–5p inhibits the Warburg effect by suppressing hexokinase 2 in LIHC (Xu et al., 2021), miR-101–3p inhibits the Warburg effect by suppressing Beclin-1-mediated autophagy (Sun et al., 2019), and miR-144-3p-mediated EIF4G2 dysregulation promotes the development of LIHC via the ERK pathway (Li et al., 2021). It was also shown that downregulation of miR-101–3p expression can promote the proliferation and migration of LIHC cells (Sheng et al., 2014). As for the CAMSAP1 regulatory miRNA, it has been previously reported that the downregulation of CAMSAP1 in primary human osteoblasts and laryngeal squamous cell carcinoma is caused by upregulation of miR-126 (Sun et al., 2014; Strassburg et al., 2017). Our study also found that miR-101–3p is the regulatory miRNA of CAMSAP1 expression in LIHC. Based on the ceRNA hypothesis (Tay et al., 2014; Qi et al., 2015), potential lncRNA regulators of the miR-101-3p-CAMSAP1 axis are carcinogenic in LIHC. Therefore, upstream lncRNAs were evaluated, and 16 possible candidates were identified. Expression, diagnosis, and survival analyses identified two lncRNAs (AC145207.5 and LINC01748) most likely to be upregulated. These two lncRNAs reportedly function as oncogenes in various malignant tumors or autoimmune disease. For example, AC145207.5 (RP11-498C9.15) plays a pivotal role in rheumatoid arthritis by modulating both miRNAs and gene expression (Dolcino et al., 2019). Moreover, LINC01748 regulates the miRNA-520a-5p/HMGAl axis to exert carcinogenic effects in non-small cell lung cancer (Tan et al., 2022). Collectively, the AC145207.5/LINC01748-miR-101-3p-CAMSAP1 axis has been identified as a potential regulatory pathway in LIHC.

The tumor microenvironment is primarily composed of tumor cells, immune cells, and other cells including tumor-associated fibroblasts, extracellular matrix, vascular system, and their interacting cytokines and chemokines, and plays an important role in tumor progression (Reinfeld et al., 2021). Previous studies have confirmed that immune infiltration can influence the efficiency and efficacy of chemotherapy, radiotherapy, or immunotherapy in patients with cancer (Thorsson et al., 2018; Hiam-Galvez et al., 2021; Ruf et al., 2021). Although significant advances have been made in the immunotherapy field, challenges persist that impede its effectiveness. Therefore, identifying novel targets and biomarkers is the key to further improving the efficacy of immunotherapy. Meanwhile, a comprehensive understanding of immune infiltration is particularly important for patients with cancer to ensure that the most efficient and individualized immunotherapy strategy is selected. Our research revealed that CAMSAP1-related genes were enriched in cancer and the immune system. Our work further indicated that CAMSAP1 was positively correlated with the major types of immune cells, suggesting that tumor immune infiltration may exert an antitumor effect in CAMSAP1-mediated LIHC. However, the effectiveness of immunotherapy depends not only on immune cell infiltration but also on the regulation of immune checkpoint genes (Ruf et al., 2021). High CAMSAP1 expression was positively related to immune checkpoints, in particular CD274 (Rho >0.3, p < 0.001). CD274, also known as programmed cell death ligand 1 (PD-L1), is overexpressed in tumor cells to perform immune escape function by binding to PD-1 on the surface of CD8+ T cell (Hoos, 2016). Indeed, antibodies or drugs targeting PD-L1 have proven effective and well-tolerated for various cancers, including LIHC (Cheng et al., 2020). Moreover, our study implied that targeting CAMSAP1 may reduce immune escape.
caused by PD-L1 and improve the immunotherapeutic effect elicited by anti-PD-L1 in LIHC patients. CAFs, another TME component, participate in immunosuppression, and promote tumor growth and survival by interacting with tumor cells, and are associated with poor patient outcomes (Mhaidly and Mehta-Grigoriou, 2021). Noteworthy, CAMSAPI was
markedly correlated with CAFs but did not correlate with TMB or MSI in LIHC. ICB treatment prediction confirmed that compared with LIHC patients with high CAMSAP1 expression, the low-expression group showed better treatment effect. Combined with clinical features, ICB treatment strategy was more effective for patients with early LIHC.

Taken together, CAMSAP1 expression is associated with the diagnosis, progression, prognosis, and immunotherapy outcome of LIHC. During the initiation and malignant progression of LIHC, besides genetic alteration and DNA methylation, AC145207.5/LINC01748-miR-101-3p-mediated CAMSAP1 overexpression induces LIHC with
immune cell infiltration. However, immune checkpoints, mainly CD274 (PD-L1), and CAFs are also found to be positively correlated with CAMSAP1 expression, implying immune escape and a suppressed immune infiltrating microenvironment, thereby leading to poor prognosis. Targeting CAMSAP1 may improve the immunotherapy effect of ICB treatment, thus induces favorable prognosis (Figure 7F). Our study provides novel insights for the further exploration of LIHC. Elucidating the potential role of CAMSAP1 in immunotherapy will bring new hope for LIHC treatment, which is expected to become a personalized treatment option for patients with LIHC. However, further basic experiments and more clinical trials are required for these findings.

Conclusion

In this study, for the first time, we demonstrate that besides genetic alteration and DNA methylation, AC145207.5/LINC01748-miR-101-3p-mediated CAMSAP1 upregulation in advanced LIHC leads to poor prognosis with suppressed tumor immune infiltration, representing a potential diagnostic and prognostic biomarker as well as a promising immunotherapy target for LIHC.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Author contributions

SZ contributed to the conception of the study. WW designed the study and wrote the manuscript. WW, JZ, YW, and YX organized the databases and performed the statistical analyses. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the Zhejiang Provincial Natural Science Foundation of China (LY19H160032).

Acknowledgments

We thank the members of our research center for inspiring discussion.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.916847/full#supplementary-material

References

Ahn, J. C., Teng, P. C., Chen, P. J., Posadas, E., Tseng, H. R., Lu, S. C., et al. (2021). Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. *Hepatology* 73 (1), 422–436. doi:10.1002/hep.31165

Anastasiadou, E., Jacob, L. S., and Slack, F. J. (2018). Non-coding RNA networks in cancer. *Nat. Rev. Cancer* 18 (1), 5–18. nature12986/nrc.2017.99

Atherton, J., Luo, Y., Xiang, S., Yang, C., Rai, A., Jiang, K., et al. (2019). Structural determinants of microtubule minus end preference in CAMSAP/ssp4 family of animal proteins. *Nat. Commun.* 10 (1), 5236. doi:10.1038/s41467-019-13247-6

Bai, S. W., Herrera-Abreu, M. T., Rohn, J. L., Racine, V., Tajadura, V., Suryavanshi, N., et al. (2011). Identification and characterization of a set of conserved and new regulators of cytoskeletal organization, cell morphology and migration. *BMC Biol.* 9, 54. doi:10.1186/1741-7007-9-54

Baines, A. J., Bignone, P. A., King, M. D., Maggs, A. M., Bennett, P. M., Pinder, J. C., et al. (2009). The CKK domain (DUF1781) binds microtubules and defines the CAMSAP/ssp4 family of animal proteins. *Mol. Biol. Evol.* 26 (9), 2005–2014. doi:10.1093/molbev/msp115

Bonneville, R., Krook, M. A., Kauto, E. A., Miya, J., Wing, M. R., Chen, H. Z., et al. (2017). Landscape of microsatellite instability across 39 cancer types. *JCO Precis. Oncol.* 2017, 1–15. doi:10.1200/PO.17.00073

Chen, Y., Zheng, J., Li, X., Zhu, L., Shao, Z., Yan, X., et al. (2020). Wdr47 controls neuronal polarization through the camsap family microtubule minus-end-binding proteins. *Cell. Rep.* 31 (3), 107526. doi:10.1016/j.celrep.2020.107526

Cheng, A. L., Hsu, C., Chan, S. L., Choo, S. P., and Kudo, M. (2020). Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. *J. Hepatol.* 72 (2), 307–319. doi:10.1016/j.jhep.2019.09.025
Dolcino, M., Tinazzi, E., Puccetti, A., and Lunardi, C. (2019). Long non-coding RNAs target pathogenetically relevant genes and pathways in rheumatoid arthritis. Cell & Gene 8 (8), e1816. doi:10.1039/c9fg00816e

Frost, F. G., Cherukuri, P. F., Milanovich, S., and Boerkoel, C. F. (2020). Pan-cancer RNA-seq data stratifies tumours by some hallmarks of cancer. J. Cell. Med. 24 (1), 418–430. doi:10.1111/jcm.14746

Gao, B., and Bataller, R. (2011). Alcoholic liver disease: Pathogenesis and new therapeutic targets. Gastroenterology 141 (5), 1572–1585. doi:10.1053/j.gastro.2011.09.002

Goodson, H. V., and Jonasson, E. M. (2018). Microtubules and microtubule-associated proteins. Cold Spring Harb. Perspect. Biol. 10 (6), a026808. doi:10.1101/cshperspect.a026808

Hendershot, M. C., and Vale, R. D. (2014). Regulation of microtubule minus-end dynamics by CAMSAPs and Patronin. Proc. Natl. Acad. Sci. U. S. A. 111 (16), 5860–5865. doi:10.1073/pnas.1403131111

Hiam-Galver, K. J., Allen, B. M., and Spitler, M. H. (2021). Systemic immunity in cancer. Nat. Rev. Cancer 21 (6), 345–359. nature12986/14168-021-00347-z

Hindson, J. (2021). Molecular landscape of NASH-HCC. Nat. Rev. Gastroenterol. Hepatol. 18 (7), 456. doi:10.1038/s41575-021-00478-6

Hoadley, K. A., Yau, C., Wolf, D. M., Cherniack, A. D., Tamborero, D., Ng, S. et al. (2014). Multiplatform analysis of 12 cancer types reveals molecular dependencies and mutations of the matrisome. Cells 3 (8), a022608. doi:10.3389/cells.2021.00268

Jackson, J. R., Patrick, D. R., Dar, M. M., and Huang, P. S. (2007). Targeted anti-mitotic therapies: Can we improve on tubulin agents? Nat. Rev. Drug Discov. 6, 448–460. doi:10.1038/nrd2369

Jiang, K., Faltova, L., Hua, S., Capitani, G., Prota, A. E., Landgraf, C., et al. (2018). Microtubules and microtubule-mediated noncentrosomal microtubule acetylation drives hepatocellular carcinoma microenvironment. Nature 553 (7688), 282–288. doi:10.1038/s41586-021-00344-1

Jin, S., Xu, T., Chen, Z., Yu, L., Chen, Y., and Wang, K. (2014). CAMSAP2–miR-126 modulates the tumor microenvironment by targeting Foxa2 in cancer. Oncotarget 5 (24), 16785–16794. doi:10.18632/oncotarget.3280

Jin, X., Li, J., Liu, S., Zhou, H., Qu, L. H., and Yang, J. H. (2014). starBase v2.0: microRNA targets predicted in large-scale CLIP-Seq data. Mol. Cell 54 (5), 1015–1024. doi:10.1016/j.molcel.2014.03.033

Jung, Y. S., Lee, J., Sung, G. Y., Hwang, S. S., Lee, J. Y., and Kim, J. H. (2018). High-quality survival outcome analytics. Cell 173 (2), 400–416. doi:10.1016/j.cell.2018.02.052

Liu, X. Y., Li, Y., Ji, K. K., Zhu, J., Ling, P., Zhou, T., et al. (2020). Genome-wide codon usage pattern analysis reveals the correlation between codon usage bias and gene expression in Cuscuta australis. Genomics 112 (4), 2695–2702. doi:10.1016/j.ygeno.2020.03.002

Love, M. I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15 (12), 550. doi:10.1186/s13059-014-0550-9

Lundborg, Bave, A., Bergquist, A., Bottai, M., Warnqvist, A., Von Seth, E., and Nordenvall, C. (2021). Increased risk of cancer in patients with primary sclerosing cholangitis. Hepatol. Int. 15, 1174–1182. doi:10.1007/s12245-021-10214-6

Marcucci, F., and Rumi, C. (2021). The tumor-promoting effects of the adaptive immune system: A cause of hyperprogressive disease in cancer? Cell. Mol. Life Sci. 78 (3), 853–865. doi:10.1007/s00018-020-03606-4

Men, C., Chai, H., Song, X., Li, Y., Du, H., and Ren, Q. (2017). Identification of DNA methylation associated gene signatures in endometrial cancer via integrated analysis of DNA methylation and gene expression systematically. J. Gynecol. Oncol. 28 (6), e83. doi:10.3802/jege.2017.28.e83

Miaud, R., and Mechta-Grigoryeu, F. (2021). Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immuno. Res. 390 (2), 259–272. doi:10.1186/s12978-019-01254-5

Olynyk, J. K., and Ramm, G. A. (2021). Risk of liver cancer in HFE-hemochromatosis. Gastroenterology 161, 1718–1719. doi:10.1053/j.gastro.2021.08.025

Pawlowski, J. M. (2004). Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 12 (2), 96–102. doi:10.1016/j.tim.2003.12.005

Qi, X., Zhang, D. H., Wu, N., Xiao, J. H., Wang, X., and Ma, W. (2015). ceRNA in cancer: possible functions and clinical implications. J. Med. Genet. 52 (10), 710–718. doi:10.1136/jmedgenet-2015-103334

Rensfeld, B. I., Madden, M. Z., Wolf, M. M., Chytrý, A., Bader, J. E., Patterson, A. R., et al. (2021). Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593 (7858), 282–288. doi:10.1038/s41586-021-00344-1

Richardson, C. E., Spiller, K. A., Cueva, J. G., Pettino, J., Goodman, M. B., and Shen, K. (2014). PTEN–1, a microtubule minus-end binding CAMSAP homolog, promotes microtubule function in Caenorhabditis elegans neurons. Elife, e04198. doi:10.7554/elife.04198

Ruf, B., Heinrich, B., and Greten, T. F. (2021). Immunobiology and immunotherapy of HCC: Spotlight on innate and innate-like immune cells. Cell. Mol. Immunol. 18 (1), 112–127. nature29866/41432-020-00572-w

Sheng, Y., Li, J., Zou, C., Wang, S., Can, Y., Zhang, J., et al. (2014). Downregulation of miR-101-3p by hepatitis B virus promotes proliferation and migration of hepatocellular carcinoma cells by targeting Rb. J. Exp. Clin. Cancer Res. 33 (1), 1678. doi:10.1186/1756-9966-33-1678

Sun, W., Zhang, Q., Wu, Z., and Xue, N. (2019). miR-101-3p sensitizes hepatocellular carcinoma cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy. Int. J. Clin. Exp. Pathol. 12 (6), 2056–2065.

Sun, X., Wang, Z. M., Song, Y., Tai, X. H., Ji, W. Y., and Gu, H. (2014). MicroRNA-126 modulates the tumor microenvironment by targeting camagged, regulated miR-126 regulated spectrum-miR-associated protein 1 (Camsap1). J. Cell. Biochem. 115 (7), 1756–1763. doi:10.1002/jcb.25384

Tan, Y., Xu, F., Xu, L., and Cui, J. (2022). Long noncoding RNA LINC01748 exerts carcinogenic effects in nonsmall cell lung cancer cell lines by regulating the miRNAS20a/3p/HMGAA1 axis. Int. J. Mol. Med. 49 (2), 22. doi:10.3892/ijmm.2021.5077

Tay, Y., Rinn, J., and Pandolfo, P. P. (2014). The multilayered complexity of ceRNA crosstalk and competition. Nature 505 (7483), 344–352. doi:10.1038/nature12198

Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T. H., et al. (2018). The immune landscape of cancer. Immunity 48 (4), 812–830. e814. doi:10.1016/j.immuni.2018.03.023
Trepo, C., Chan, H. L., and Lok, A. (2014). Hepatitis B virus infection. *Lancet* 384 (9959), 2053–2063. doi:10.1016/S0140-6736(14)60220-8

Vivian, J., Rao, A. A., Nothaft, F. A., Ketchum, C., Armstrong, J., Novak, A., et al. (2017). Teuli enables reproducible, open source, big biomedical data analyses. *Nat. Biotechnol.* 35 (4), 314–316. doi:10.1038/nbt.3772

Wang, H. W., Hsieh, T. H., Huang, S. Y., Chau, G. Y., Tung, C. Y., Su, C. W., et al. (2013). Forfeited hepatogenesis program and increased embryonic stem cell traits in young hepatocellular carcinoma (HCC) comparing to elderly HCC. *BMC Genomics* 14, 736. doi:10.1186/1471-2164-14-736

Wattanathamsan, O., Chetprayoon, P., Chantaravisoot, N., Wongkongkathep, P., Chanvorachote, P., and Pongrakhananon, V. (2021). CAMSAP3 depletion induces lung cancer cell senescence-associated phenotypes through extracellular signal-regulated kinase inactivation. *Cancer Med.* 10 (24), 8961–8975. doi:10.1002/cam4.4380

Wu, M., Wang, Y., Liu, H., Song, L., and Ding, J. (2020). Genomic analysis and clinical implications of immune cell infiltration in gastric cancer. *Biosci. Rep.* 40 (5), BSR20193308. doi:10.1042/BSR20193308

Xu, F., Yan, J. J., Gan, Y., Chang, Y., Wang, H. L., He, X. X., et al. (2019). miR-885-5p negatively regulates Warburg effect by silencing hexokinase 2 in liver cancer. *Mol. Ther. Nucleic Acids* 18, 308–319. doi:10.1016/j.omtn.2019.09.002

Yi, L., Wu, G., Guo, L., Zou, X., and Huang, P. (2020). Comprehensive analysis of the PD-L1 and immune infiltrates of m(6)A RNA methylation regulators in head and neck squamous cell carcinoma. *Mol. Ther. Nucleic Acids* 21, 299–314. doi:10.1016/j.omtn.2020.06.001

Yi, Y., Qiu, Z., Yao, Z., Lin, A., Qin, Y., Sha, R., et al. (2021). CAMSAP1 mutation correlates with improved prognosis in small cell lung cancer patients treated with platinum-based chemotherapy. *Front. Cell. Dev. Biol.* 9, 770811. doi:10.3389/fcell.2021.770811

Yu, G., Wang, L. G., Han, Y., and He, Q. Y. (2012). clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* 16 (5), 284–287. doi:10.1089/omi.2011.0118

Zhou, Z., Xu, H., Li, Y., Yang, M., Zhang, R., Shiraiishi, A., et al. (2020). CAMSAP1 breaks the homeostatic microtubule network to instruct neuronal polarity. *Proc. Natl. Acad. Sci. U. S. A.* 117 (36), 22193–22203. doi:10.1073/pnas.1913177117
| **Glossary**                  | **DEFINITION**                                                |
|-------------------------------|---------------------------------------------------------------|
| LIHC                          | Liver hepatocellular carcinoma                               |
| MT                            | microtubule                                                  |
| CAMSAP                        | Calmodulin-regulated spectrin-associated protein              |
| nRNA                          | non-coding RNA                                               |
| ICB                           | immune checkpoint blockade                                   |
| microRNA                      | miRNA                                                        |
| IncRNA                        | long non-coding RNA                                          |
| TCGA                          | The Cancer Genome Atlas                                      |
| GTEx                          | Genotype-Tissue Expression                                   |
| GEO                           | Gene Expression Omnibus                                      |
| IHC                           | immunohistochemical                                          |
| HPA                           | Human Protein Atlas                                          |
| AOD                           | average optical density                                      |
| CNA                           | copy-number alteration                                       |
| IncRNA                        | long non-coding RNA                                          |
| ENCORI                        | Encyclopedia of RNA Interactomes                             |
| ROC                           | receiver operating characteristic                           |
| AUC                           | area under the curve                                         |
| OS                            | overall survival                                             |
| DSS                           | disease-specific survival                                    |
| PFI                           | progression-free interval                                    |
| KM                            | Kaplan–Meier                                                |
| OR                             | odds ratio                                                   |
| CI                            | confidence interval                                          |
| HR                            | hazard ratio                                                 |
| C-index                       | concordance index                                            |
| DEG                           | differentially expressed gene                                |
| GO                             | Gene Ontology                                               |
| GSEA                          | Gene Set Enrichment Analysis                                 |
| CC                             | cellular component                                           |
| MF                             | molecular function                                           |
| BP                             | biological pathway                                          |
| TIMER2                        | Tumor Immune Estimation Resource 2                           |
| CAFs                          | cancer-associated fibroblasts                                |
| TMB                           | tumor mutation burden                                        |
| MSI                           | microsatellite instability                                    |
| TIDE                          | Tumor Immune Dysfunction and Exclusion                       |
| CTL                           | cytotoxic T lymphocyte                                       |
| ACC                           | adrenocortical carcinoma                                     |
| BLCA                          | bladder urothelial carcinoma                                 |
| BRCA                          | breast infiltrating carcinoma                                |
| CESC                          | cervical squamous cell carcinoma and endocervical adenocarcinoma |
| CHOL                          | cholangiocarcinoma                                           |
| COAD                          | colon adenocarcinoma                                         |
| DLBC                          | diffuse large B cell lymphoma                                |
| ESCA                          | esophageal carcinoma                                         |
| GBM                           | glioblastoma multiforme                                      |
| HNSC                          | head and neck squamous cell carcinoma                        |
| KICH                          | kidney chromophobe                                           |
| KIRC                          | kidney renal clear cell carcinoma                            |
| KIRP                          | kidney renal papillary cell carcinoma                        |
| LAML                          | acute myeloid leukemia                                       |
| LGG                           | low-grade glioma                                             |
| LUAD                          | acute myeloid leukemia                                       |
| LSC                           | lung squamous cell carcinoma                                 |
| MESO                          | mesothelioma                                                 |
| OV                             | ovarian serous cystadenocarcinoma                            |
| PAAD                          | pancreatic adenocarcinoma                                    |
| PCPG                          | pheochromocytoma and paraganglioma                           |
| PRAD                          | prostate adenocarcinoma                                      |
| READ                          | rectum adenocarcinoma                                        |
| SARC                          | sarcoma                                                      |
| SKCM                          | skin cutaneous melanoma                                      |
| STAD                          | stomach adenocarcinoma                                       |
| TGCT                          | testicular germ cell tumors                                  |
| THCA                          | thyroid carcinoma                                            |
| THYM                          | thymoma                                                      |
| UCEC                          | uterine corpus endometrial carcinoma                         |
| UCS                           | uterine carcinosarcoma                                       |
| UVM                           | uveal melanoma                                               |
| ceRNA                         | competing endogenous RNA                                     |